gdc-0973 and Ganglioglioma

Post-surgical management of low grade gangliogliomas is controversial with paucity of data for the use of chemotherapy. BRAF mutations are present in a number of glioma subtypes and offer an opportunity for treatment with targeted therapy.. A 32-year-old man with an unresectable, BRAF V600E mutant, WHO grade 1 ganglioglioma is commenced on combination BRAF and MEK inhibition (vemurafenib and cobimetinib). Partial radiological and clinical response was noted after 13 weeks of treatment. Treatment complication with grade 2 skin and liver toxicity was resolved with dose interruption and reduction.. Combination BRAF and MEK inhibition present a safe and feasible treatment strategy in unresectable BRAF V600E mutant low grade ganglioglioma.

Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Azetidines; Brain Neoplasms; Ganglioglioma; Humans; Male; Mitogen-Activated Protein Kinase Kinases; Mutation; Piperidines; Proto-Oncogene Proteins B-raf; Vemurafenib

Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azetidines; Brain Neoplasms; Drug Resistance, Neoplasm; Ganglioglioma; Humans; Male; Mutation; Piperidines; Proto-Oncogene Proteins B-raf; Vemurafenib